Fig. 3. The injection of the A2AR agonist CGS21680 into the lateral septum (LS) suppresses c-Fos expression in the LS and increases c-Fos expression in the lateral habenula (LHb) and dorsomedial hypothalamus (DMH).
a Schematic protocol to test the role of the A2AR agonist CGS21680 on LS outputs. b Representative immunofluorescence images and average bar graph illustrating the decreased expression of c-Fos in the LS (n = 3 mice/group, 9 slices/mouse, Unpaired t test, p = 0.0005, t(4) = 10.38). Scale bar: 500 μm. LV, lateral ventricle. c Representative immunofluorescence images and average bar graphs illustrating the increased expression of c-Fos in the DMH (n = 3 mice/group, 9 slices/mouse, Unpaired t test, p = 0.0448, t(4) = 2.884) and LHb (n = 3 mice/group, 9 slices/mouse, Unpaired t test, p = 0.0075, t(4) = 4.648) after focal microinjection of the A2AR agonist CGS21680 into the LS. Scale bars: 500/200 μm. Arc, arcuate hypothalamic nucleus; D3V, dorsal third ventricle; MHb, medial habenula; VMH, ventromedial hypothalamic nucleus; 3V, third Ventricle, Pe, periventricular hypothalamic. Data were shown as mean ± SEM. *p < 0.05, ***p < 0.001; n.s., no significant difference. Source data are provided as a Source Data file.